{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-052029","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.689958+00:00","generated_at":"2026-05-28T23:27:03.736163+00:00","sec_items":["1.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Provectus assigns exclusive ophthalmic license to majority-owned subsidiary VisiRose","bullets":["Assigns exclusive license with University of Miami for photodynamic antimicrobial therapy in ophthalmology to VisiRose, effective Dec 9, 2024.","VisiRose is a majority-owned subsidiary focused on developing rose bengal sodium for ophthalmology diseases and disorders.","University of Miami approved assignment and novation, releasing Provectus from future obligations under the license.","Provectus grants VisiRose a non-exclusive, worldwide, royalty-free license to Licensee Background IP as needed.","Agreement reflects Provectus's strategy to separate ophthalmic assets into a dedicated subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-052029","json":"https://secwatch.observer/filing/0001493152-24-052029.json","markdown":"https://secwatch.observer/filing/0001493152-24-052029.md","text":"https://secwatch.observer/filing/0001493152-24-052029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224052029/0001493152-24-052029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224052029/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:27:03.736163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}